Table 2.
Effects of PrEP on HIV infection.
| Study | Outcome | Risk reduction# | |
|---|---|---|---|
| PrEP arm (TDF-based regimen) | Control | ||
| CDC safety study | 0 infections among 101 persons (PrEP immediate arm) | 3 infection among 99 persons (placebo immediate arm) | |
| NCT01632995 | 2 infections among 557 persons during follow-up | ||
| HPTN-069 | 0 infections among 100 persons (PrEP immediate arm) | ||
| Ipergay | 2 infection among 199 persons | 14 infection among 201 persons | 86% in relative reduction (95% CI 40–98, p = 0.002) |
| Ipergay OLE | 0.19 per 100 person-year | 6.6 per 100 person-years | 97% in relative reduction (95% CI 81–100) |
| iPrEx | 36 infections among 1251 persons | 64 infection among 1225 persons | 44% in relative reduction (95% CI 15–63, p = 0.005) |
| iPrEx OLE | 1.8 infections per 100 person-year | 2.6 infection per 100 person-year | |
| KPSF | 0 infections among 657 initiating PrEP | ||
| PATH-PrEP | 1 infection among 297 persons | ||
| PROUD-pilot phase | 3 infections among 275 persons | 20 infections among 269 persons | 86% in relative reduction (95%CI 64–96, p = 0.001) |
| PROUD-second phase | 1 infection among 206 persons | 20 infections among 269 persons | |
| ATN110 YSMS | 4 infections among 200 persons | ||
| HPTN073BSMS | 5 infections among 178 persons | ||
#
We reported risk reduction based on original papers.